Comparative effectiveness of Alfuzosin (Alfuprost® MR) and Solifenacin (Vesigamp) combination therapy in patients with BPH and overactive bladder, with moderate and severe symptoms of lower urinary tract dysfunction

Introduction. Recently, the first generalized data on the efficacy and safety of alfuzosin (Alfuprost’ MR) and solifenacin (Vesigamp) combination therapy (CT) in patients with LUTS/BPH and hyperactive bladder (ОАВ) have been published based on the results of the multicenter observational «AVIATOR» study. This was the first study of alfuzosin and solifenacin combination, in which a set of validated questionnaires was used to assess symptoms. Crucially, the program did not include BPH patients with the presence of middle lobe and/or intravesical protrusion of more than 10 mm, potentially having a mechanical type of bladder outlet obstruction (BOO). The study showed impressive results on the effect of drugs on the symptoms frequency and severity of symptoms. The aim of this study was to evaluate the clinical efficacy of alfuzosin 10 mg/day and solifenacin 5 mg/day for three months in patients with LUTS/BPH and OAB with moderate to severe symptoms.